Talem Therapeutics Announces the Creation of its Scientific Committee

The Committee consists of a selection of internationally recognized visionary scientists and experts from a broad range of disciplines.


IPA entered into an antibody discovery program with Entos Pharmaceuticals, Inc.

IPA has entered into an antibody discovery program with Entos Pharmaceuticals to develop a therapeutic candidate against an immuno-oncology target.


ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

IPA’s proprietary B cell SelectTM platform exhibits a minimum success rate of 94 %.


IPA Announces Onboarding of Clients Using IPA’s Proprietary High-Throughput B-Cell Select™ and DeepDisplay™

IPA is fully prepared to respond to the demand and use of alternative transgenic species in novel antibody generation.


ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt- Surrogate-Fc Growth Factor

The Wnt-Surrogate-Fc Fusion Protein is an important growth factor in the field of organoid technology


ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Attendees will obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Items 1 to 6 of 70 total

Show per page